marketing-medtech

**Founder:** Julien Priour — Co-founder & Directeur Général (Managing Director), AI DiagMe / Smart Medical Care SAS
**Background:** serial_entrepreneur | verified: True — Julien Priour (French national, based in Taiwan, HEC Paris MBA, trilingual Mandarin/English/French) is a multi-venture founder, consistent with "serial entrepreneur." He is Co-founder & Managing Director of AI DiagMe / Smart Medical Care SAS (an AI lab-results interpretation platform). Before that he was Co-Founder & GM at Blyng (an AI virtual assistant for real estate agents; other founders: Sasha Serafimovski, Alexandre Boulenger as CEO, Julien Vidal). UK Companies House lists him as director of three further UK companies: SNOWFLOW AI LTD (appointed 2020-03-18, active), OTOMATE LTD (appointed 2022-12-30, now dissolved), and BLEES TECHNOLOGIES LIMITED (2021-06-21 to 2025-04-28). His earlier career included roles at Amadeus and Intuiface (travel/interactive tech). The pattern of founding and directing several companies over multiple years supports the "serial entrepreneur" characterization.
**Stage / fundraise:** Seed / very early (SAS created 2024-09-06) / No confirmed priced/announced round. Strong indirect capital signal: 100%-style control by AI INVEST HOLDING (a finance/holding entity, NAF 64.20Z) and registered share capital ~1.015M EUR point to structured/owner capital. Treat as "likely funded by holding, actively investing in build" rather than a confirmed VC round.
**Regulatory trigger:** High. AI DiagMe interprets blood/urine/lab results and generates a personalized health report — a software function that interprets clinical data is squarely in scope for SaMD / EU MDR classification (Rule 11) and IEC 62304 lifecycle. They already host on HDS-certified servers and lean on RGPD + a 9-doctor scientific committee, but interpretation-of-results SaMD typically needs an MDR CE path + IEC 62304 technical file (where OmDev's SOUP register + requirements-to-code-to-test traceability directly feed the file). They currently position it as an "information tool, not a diagnosis" — a fragile boundary that an MDR review could push into device territory.
**Email:** Jp@aidiagme.com (confidence high) — Published directly on the Eurobiomed member directory page for "SMART MEDICAL CARE SAS", which lists Contact: Mr. Julien PRIOUR, Email: Jp@aidiagme.com (https://www.eurobiomed.org/en/connecter/nos-membres/smart-medical-care-sas/). General inbox contact@aidiagme.com is also published on aidiagme.com. Pattern confirmed: firstinitiallastname@aidiagme.com.
**LinkedIn:** https://uk.linkedin.com/in/julien-priour (also https://www.linkedin.com/in/julienppoint/ ; company: https://fr.linkedin.com/company/aidiagme ) **Website:** https://aidiagme.fr/
**Score:** 13 -> Tier A
**Hook:** AI DiagMe interprets lab results — that puts you on an MDR / IEC 62304 collision course, yet you're ~18 months in with two DGs and a holding behind you but no in-house CTO or dev team to carry the technical file. OmDev gives you a senior dev squad + a dedicated CTO for a fixed monthly price (~3x cheaper than hiring that team in Nice), and our build pipeline produces the compliance evidence — a SOUP register signed every build and requirements-to-code-to-test traceability — that drops straight into your IEC 62304/MDR file, while you keep 100% ownership of the code.

---

## Founder & background
**Julien Priour** (b. 1981) — Co-founder & Directeur Général of **Smart Medical Care SAS** (product: **AI DiagMe**); HEC Paris MBA, trilingual, ~20 yrs experience — a business/operator (serial-entrepreneur) profile, not a technical founder ([LinkedIn](https://uk.linkedin.com/in/julien-priour), [Pappers](https://www.pappers.fr/dirigeant/julien_priour_1981-10)).
Co-DG **Eric Benzakin** (b. 1976). The company is owned by **AI INVEST HOLDING** (NAF 64.20Z), whose president **Pouya Nosrati Tehrani** is a real-estate/hospitality **investor** (Persepolis Investment, Hospitality Capital Invest; La French Care member) — investor/operator-led build ([API](https://recherche-entreprises.api.gouv.fr/search?q=931879027), [La French Care](https://www.lafrenchcare.fr/membre/nosrati-pouya/)).
No CTO appears among the registered officers.
*Why OmDev fits:* a business-led founding team with finance-side backers but no in-house tech leadership is exactly who benefits from a dedicated CTO + senior squad on tap.

## Funding & momentum
SAS created **2024-09-06** (~18-21 months old), product live, ~8 reported staff (0 declared at INSEE) ([API](https://recherche-entreprises.api.gouv.fr/search?q=932924194)).
Registered share **capital ~1,015,002 EUR** — high for an early SaaS, consistent with a capital injection from the holding rather than bootstrapping ([Pappers](https://www.pappers.fr/entreprise/smart-medical-care-932924194)).
No confirmed priced VC round found; the holding (AI INVEST HOLDING) is the funding/control vehicle.
*Why OmDev fits:* early + holding-funded + spending on build = fixed-price Dev-as-a-Service (~3x cheaper than hiring) preserves runway while accelerating the product.

## Product & regulatory
**AI DiagMe** uploads lab results (blood/urine/stool) and returns an AI-generated plain-language interpretation report in minutes; HDS-hosted on Azure France, RGPD, 9-doctor scientific committee ([aidiagme.fr](https://aidiagme.fr/)).
Interpreting clinical results is **SaMD** territory — likely **MDR Rule 11** + **IEC 62304** lifecycle; they currently frame it as an "information tool, not a diagnosis," a boundary an MDR review can challenge.
Member of French Tech, **Eurobiomed**, French Care ([Eurobiomed](https://www.eurobiomed.org/en/connecter/nos-membres/smart-medical-care-sas/)).
*Why OmDev fits:* our pipeline produces SOUP register (signed every build) + requirements-to-code-to-test traceability that feed the IEC 62304/MDR technical file (OmDev does not certify).

## Pain & buying signals
No named CTO; thin team for a regulated clinical-data product; "AI validated by doctors" claims demand documented traceability they likely don't yet have.
Interpretation-of-results scope = a looming MDR/IEC 62304 decision they appear under-resourced to execute.
Direct, published reach: **Jp@aidiagme.com** (Julien Priour, on the Eurobiomed directory) ([source](https://www.eurobiomed.org/en/connecter/nos-membres/smart-medical-care-sas/)).
*Why OmDev fits:* dedicated CTO + senior devs + built-in compliance evidence, fixed monthly price, client owns the code — references CadSmile & SpeechLink.

---
**Sources:** https://recherche-entreprises.api.gouv.fr/search?q=932924194 · https://recherche-entreprises.api.gouv.fr/search?q=931879027 · https://www.pappers.fr/entreprise/smart-medical-care-932924194 · https://www.pappers.fr/dirigeant/julien_priour_1981-10 · https://uk.linkedin.com/in/julien-priour · https://fr.linkedin.com/company/aidiagme · https://aidiagme.fr/ · https://aidiagme.com/contact-us-ai-diag-me/ · https://www.eurobiomed.org/en/connecter/nos-membres/smart-medical-care-sas/ · https://www.lafrenchcare.fr/membre/nosrati-pouya/ · https://infonet.fr/dirigeants/66aa2fb75da7ac2c4bcb0f0a/ · https://rocketreach.co/aidiagme-management_b71a3791c48a1e18